What is UNITED THERAPEUTICS Corp worth?
With the base-case assumptions below, a discounted cash flow model on UNITED THERAPEUTICS Corp's reported free cash flow gives $742.65 per share. The share price was $588.61 on November 10, 2026, 21% below that value.
Inputs from the filings
Three sets of assumptions
| Case | Growth yrs 1-5 | Discount rate | Value per share | Value vs price |
|---|---|---|---|---|
| Bear | 10.0% | 10.0% | $460.97 | -22% |
| Base | 15.0% | 9.0% | $742.65 | +26% |
| Bull | 20.0% | 8.0% | $1,267.14 | +115% |
Sensitivity: base case value per share
| 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | |
|---|---|---|---|---|---|
| 7.0% | $955.91 | $1,022.41 | $1,103.68 | $1,205.27 | $1,335.89 |
| 8.0% | $795.71 | $838.83 | $889.79 | $950.95 | $1,025.69 |
| 9.0% | $679.15 | $708.63 | $742.65 | $782.34 | $829.25 |
| 10.0% | $590.76 | $611.73 | $635.49 | $662.65 | $693.98 |
| 11.0% | $521.60 | $536.98 | $554.16 | $573.48 | $595.39 |
Where the presets come from
Base: years 1 to 5 grow at UNITED THERAPEUTICS Corp's revenue growth rate over the last 5 fiscal years (16.5% a year), held between -5% and 15%. Years 6 to 10 grow halfway between that and the long-run rate of 2.5%. Future cash is discounted at 9% a year.
Bear: 5 points less growth, 2% long-run growth, 10% discount rate. Bull: 5 points more growth (at most 25%), 3% long-run growth, 8% discount rate.
Value per share = (present value of 10 years of free cash flow + present value of everything after + cash - debt) / diluted shares.
This is a model run on assumptions, not a recommendation or a price target. Small changes in the discount rate or growth move the result a lot, as the table above shows. Change them yourself in the calculator.
Adjust the assumptions
Move the sliders for growth, long-run growth and discount rate, or switch to average free cash flow, and see the value per share change.
Adjust the assumptions